Harbin Pharmaceutical Group Co (SHSE:600664) ROCE %: 12.34% (As of Mar. 2026)


SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
78 GF Score
Price ¥3.14
GF Value ¥3.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co ROCE %?

Harbin Pharmaceutical Group Co SHSE:600664 +0.96% 78 ROCE % is 12.34% as of Mar. 2026. GuruFocus rates SHSE:600664 with a GF Score™ of 78/100 and a GF Value™ of ¥3.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Harbin Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.34%.

Harbin Pharmaceutical Group Co  (SHSE:600664) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Harbin Pharmaceutical Group Co ROCE % Related Terms

Harbin Pharmaceutical Group Co ROCE % Historical Data

* Premium members only.

The historical data trend for Harbin Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co ROCE % Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.39 15.10 12.51 15.11 9.20

Harbin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.06 5.96 7.68 6.00 12.34
SHSE:600664
78GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harbin Pharmaceutical Group Co ROCE % Calculation

Harbin Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=615.293/( ( (14615.758 - 8105.01) + (14287.659 - 7422.587) )/ 2 )
=615.293/( (6510.748+6865.072)/ 2 )
=615.293/6687.91
=9.20 %

Harbin Pharmaceutical Group Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=857.764/( ( (14287.659 - 7422.587) + (14652.541 - 7610.503) )/ 2 )
=857.764/( ( 6865.072 + 7042.038 )/ 2 )
=857.764/6953.555
=12.34 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.34% mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a ROCE % of 12.34% as of Mar. 2026.
Is Harbin Pharmaceutical Group Co's ROCE % too high?
Harbin Pharmaceutical Group Co's current ROCE % is 12.34%. The Drug Manufacturers industry median ROCE % is 7.03. Harbin Pharmaceutical Group Co's value of 12.34% is 75.5% above this industry median. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's ROCE % compare to ZTS and UTHR?
Harbin Pharmaceutical Group Co's ROCE % of 12.34% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Harbin Pharmaceutical Group Co's value of 12.34% is 75.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current ROCE % of 12.34% is 75.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current ROCE % is 12.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥3.14 — trading 10.5% below its estimated fair value. The current ROCE % is 12.34% and 75.5% above the Drug Manufacturers industry median of 7.03. Harbin Pharmaceutical Group Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current ROCE % is 12.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥3.14 is trading 10.5% below its estimated GF Value™ of ¥3.51. GuruFocus considers Harbin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:600664:

  • ROCE %: 12.34%
  • GF Value™: ¥3.51 vs. price of ¥3.14 (10.5% below fair value)
  • GF Score™: 78/100 with 2 warning signs
  • Industry Position: 75.5% above the Drug Manufacturers median

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
78GF Score

Get the complete analysis for SHSE:600664

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.14
Price
¥3.51
GF Value